Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.

Prasad Adusumilli outlines the key results of their phase I trial showing promising safety and efficacy of a mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease, and also discusses the next steps (4:09).

A phase 2 trial has demonstrated promising antitumor activity and manageable toxicity of abemaciclib in previously treated patients with p16ink4A-negative malignant mesothelioma.

Results from the phase 2 VIM trial support the use of vinorelbine in patients with malignant pleural mesothelioma whose disease has progressed following platinum-based therapy.

Neoadjuvant atezolizumab meets researcher-defined safety criteria for use in combination with cisplatin plus pemetrexed and then as postsurgical maintenance therapy for people with resectable malignant pleural mesothelioma.

Among people receiving first-line platinum-based chemotherapy for malignant pleural mesothelioma, carboplatin is associated with similar overall survival as cisplatin, show findings presented at the IASLC 2020 World Conference on Lung Cancer.

Treatment with single-agent nivolumab improves the outcomes of previously treated patients with malignant mesothelioma, suggest phase 3 study results.

medwireNews : The US FDA has approved nivolumab plus ipilimumab as a first-line treatment for unresectable malignant pleural mesothelioma.

Patients with treatment-naïve and unresectable malignant pleural mesothelioma may respond to treatment with durvalumab given alongside cisplatin and pemetrexed, suggest results from the phase 2 PrE0505 study.

Adding ramucirumab to gemcitabine may significantly improve survival outcomes for patients with malignant pleural mesothelioma who have progressed on first-line platinum–pemetrexed regimens, suggest findings from the phase 2 RAMES study presented at the virtual 2020 ASCO Annual Meeting.

Switching palliative radiation for high-dose radical hemi-thoracic radiotherapy significantly increases 2-year overall survival among patients with a new diagnosis of malignant pleural mesothelioma, delegates were told at the ESTRO 38 meeting in Milan, Italy.

Lurbinectedin has clinical activity and acceptable toxicity in the second- and third-line treatment of malignant pleural mesothelioma, say phase 2 trial investigators.

Combining tumor treating fields with standard chemotherapy could be a promising option for the first-line treatment of inoperable malignant pleural mesothelioma, say the STELLAR investigators.

Adding nintedanib to pemetrexed plus cisplatin does not improve progression-free survival for patients with advanced malignant pleural mesothelioma, say researchers who conducted a phase III trial on the basis of earlier positive findings.

Comment on: Outpatient talc pleurodesis supported for malignant pleural effusion

Preliminary results suggest a role for the combination of the CTLA-4 inhibitor tremelimumab and the PD-L1 blocker durvalumab in the treatment of inoperable pleural or peritoneal mesothelioma.

Treatment with checkpoint inhibitors could be an option for patients with relapsed malignant pleural mesothelioma, say the MAPS2 researchers who reported the survival data of patients given nivolumab alone and alongside ipilimumab.

In addition, the generic formulation may also now be used alongside cisplatin for treatment-naïve patients with unresectable malignant pleural mesothelioma.